We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Meaghan
Grabrovaz
meaghan.grabrovaz@northumbria.ac.uk
Andrew
Sturrock
andrew.sturrock@nhs.scot
Andrew
Sturrock
andrew.sturrock@nhs.scot
Disorders of bone density and structure
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
Background:
There is no standard practice for following up patients with osteoporosis. Patients have reported this as a problem, because of ongoing needs. Medicines optimisation is a term used to describe a person-centred approach to safe and effective medicines use, helping people obtain the best possible outcomes from their medicine.
Aim:
To develop a pharmacist follow-up review in general practice to support person-centred care and medicines optimisation for people on osteoporosis medicines.
Methods:
We will co-design the review with patients and healthcare professionals. We will use findings from a literature review of interventions that support patients to feel informed and adhere to osteoporosis medicines which members of this group have already undertaken on behalf of the Royal Osteoporosis Society (ROS) Bone Research Academy. The review will also be informed by an existing ROS-funded training and decision support tool (iFraP), developed for use in Fracture Liaison Services when people start medicines.
We will use focus groups with patients and healthcare professionals, and extensive PPIE/Stakeholder input to explore how, where and when the review should be delivered and how to adapt and build on the existing iFraP resources for the new review. Focus groups will be held either online or face to face giving participants choice in how they take part.
We will then test the review with a small number of patients and pharmacists to make sure it works in practice. These patients (with informed consent) will participate in the model intervention which will be audio recorded and observed by a researcher. The patient and pharmacist will then take part in a 1-1 interview with the researcher to allow participants to share their views so that the intervention can be refined.
We aim to seek further funding for a full clinical trial of the new intervention in the future.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Education or Self-Management;Psychological & Behavioural;Complex Intervention;
You can take part if:
You may not be able to take part if:
For both focus groups and In-practice Testing. Vulnerable patients (e.g. severe mental illness, learning difficulties, and dementia) and/or those unable to give informed consent will be excluded.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Andrew
Sturrock
andrew.sturrock@nhs.scot
Meaghan
Grabrovaz
meaghan.grabrovaz@northumbria.ac.uk
Andrew
Sturrock
andrew.sturrock@nhs.scot
The study is sponsored by University of Northumbria at Newcastle and funded by ROYAL OSTEOPOROSIS SOCIETY .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 56914
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
